[The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer's disease patients (neuropsychological investigation)].

Roshchina IF, Kolykhalov IV, Selezneva ND, Zharikov GA, Gerasimov NP, Gavrilova SI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 1999

PMID10629930PepBankPUB-10629930

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with mild or moderate dementia, prior Cerebrolysin improved regulatory mental components more than amiridin alone.
In plain wordsIn patients with dementia, Cerebrolysin before amiridin improved mental regulation more than amiridin alone.
Peptide
Cerebrolysin
Outcome
IncreaseRegulatory components of mental activity
Study
n = 49
Comparator
Amiridin monotherapy
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml in 150 ml of physiologic solution · intravenous · 4 weeksAs given in this study (human).
Source sentences
Summary
Comparison of the results of neuropsychologic examination both before and after the therapy showed a more pronounced improvement in the states of all regulatory and separate operational components of mental activity in combined therapy with cerebrolysin and amiridin versus monotherapy with amiridin.
3 context sentences(design, population, supporting numbers)
Summary · context
The paper presents a study concerning an influence of cerebrolysin on the efficiency of subsequent therapy with amiridin in patients with mild and moderate dementia of Altzheimer's type (DAT).
Summary · context
The patients of group 1 (23 cases) were treated by amiridin in daily dose of 80 mg during 10 weeks.
Summary · context
In group 2 (26 patients) a session of 20 intravenous infusions of cerebrolysin (30 ml in 150 ml of physiologic solution during 4 weeks) preceded the same therapy with amiridin.
Report a problemFND-1062993001
02HumanNon-randomized trialEfficacy outcome
In patients with mild or moderate dementia, prior Cerebrolysin improved separate operational mental components more than amiridin alone.
In plain wordsIn patients with dementia, Cerebrolysin before amiridin improved some mental operations more than amiridin alone.
Peptide
Cerebrolysin
Outcome
IncreaseOperational components of mental activity
Study
n = 49
Comparator
Amiridin monotherapy
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml in 150 ml of physiologic solution · intravenous · 4 weeksAs given in this study (human).
Source sentences
Summary
Comparison of the results of neuropsychologic examination both before and after the therapy showed a more pronounced improvement in the states of all regulatory and separate operational components of mental activity in combined therapy with cerebrolysin and amiridin versus monotherapy with amiridin.
3 context sentences(design, population, supporting numbers)
Summary · context
The paper presents a study concerning an influence of cerebrolysin on the efficiency of subsequent therapy with amiridin in patients with mild and moderate dementia of Altzheimer's type (DAT).
Summary · context
The patients of group 1 (23 cases) were treated by amiridin in daily dose of 80 mg during 10 weeks.
Summary · context
In group 2 (26 patients) a session of 20 intravenous infusions of cerebrolysin (30 ml in 150 ml of physiologic solution during 4 weeks) preceded the same therapy with amiridin.
Report a problemFND-1062993002
03HumanNon-randomized trialEfficacy outcome
In patients with higher mental function disturbances, prior Cerebrolysin reduced anterior frontal and deep brain symptomatology versus amiridin alone.
In plain wordsIn patients with mental function disturbances, Cerebrolysin before amiridin reduced related symptoms more than amiridin alone.
Peptide
Cerebrolysin
Outcome
DecreaseHigher mental function pathological symptoms
Study
n: not reported in source
Comparator
Amiridin monotherapy
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml in 150 ml of physiologic solution · intravenous · 4 weeksAs given in this study (human).
Source sentences
Summary
In patients of group 2 with disturbances of higher mental functions the pathological symptomatology connected with anterior frontal and deep structures of brain was significantly decreased as compared with the patients from group 1.
3 context sentences(design, population, supporting numbers)
Summary · context
The paper presents a study concerning an influence of cerebrolysin on the efficiency of subsequent therapy with amiridin in patients with mild and moderate dementia of Altzheimer's type (DAT).
Summary · context
The patients of group 1 (23 cases) were treated by amiridin in daily dose of 80 mg during 10 weeks.
Summary · context
In group 2 (26 patients) a session of 20 intravenous infusions of cerebrolysin (30 ml in 150 ml of physiologic solution during 4 weeks) preceded the same therapy with amiridin.
Report a problemFND-1062993003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.